Red Orbit (Free subscription) | 09/09/2008
AGI Therapeutics Interim financial results for the six months ended 30 June 2008 -- ARDIS-1 now 75% enrolled -- Dublin, Ireland, 9 September 2008 - AGI Therapeutics plc ("AGI" or the"Company") (AIM, IEX: AGI), a speciality pharmaceutical development company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June 2008.
ireland.com (Free subscription) | 09/09/2008
Gastro-intestinal drugs development firm AGI Therapeutics has reported an $8.9 million pre-tax loss for the six months to the end of June.
Market Wire - Pharmaceuticals and Biotech (Free subscription) | 21/05/2008
DUBLIN, IRELAND (MARKET WIRE) AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the key pharmacology and clinical findings related to Rezular (arverapamil, AGI-003), which is being developed by the Company as a gastrointestinal-selective agent for the treatment of diarrhoea-predominant irritable...
Red Orbit (Free subscription) | 15/05/2008
AGI Therapeutics to present RezularTM pharmacological and clinical findings at DDW in San Diego -- 8 a.m.
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 14/05/2008
Dublin, Ireland (MARKET WIRE)
The Irish Times (Free subscription) | 04/04/2008
GASTRO-INTESTINAL drugs development company AGI Therapeutics lost €14.1 million last year, but claimed progress on bringing its Rezular drug to market.
Red Orbit (Free subscription) | 03/04/2008
AGI Therapeutics has reported key findings of a clinical study to assess the pharmacokinetic profile of arbaclofen, which is being developed for the treatment of gastroparesis.
Medical News Today (Free subscription) | 03/04/2008
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, announces the key findings of a clinical study to assess the pharmacokinetic profile of arbaclofen (AGI-006), which is being developed for the treatment of gastroparesis, a significant gastric condition amongst diabetics.
Market Wire (Free subscription) | 03/04/2008
Dublin, Ireland (MARKET WIRE)
Red Orbit (Free subscription) | 02/04/2008
AGI announces key findings of clinical PK study of arbaclofen (AGI-006) Dublin, Ireland, 2 April 2008 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the key findings of a clinical study to assess the pharmacokinetic profile of arbaclofen (AGI-006), which is being developed for the treatment...
Market Wire (Free subscription) | 18/03/2008
Dublin, Ireland (MARKET WIRE)
The Earth Times Online Newspaper (Free subscription) | 18/03/2008
Dublin, Ireland -- 03/18/08 -- AGI Therapeutics PLC Notification of Results AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company f..
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 05/03/2008
Dublin, Ireland (MARKET WIRE)
